# Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

> **NCT02264002** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 119 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cilobradine low dose 1
- **DRUG:** Cilobradine low dose 2
- **DRUG:** Cilobradine medium dose
- **DRUG:** Cilobradine high dose 1
- **DRUG:** Cilobradine high dose 2
- **DRUG:** Metoprolol succinate tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02264002
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2003-11
- **Final completion:** —
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264002, "Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02264002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*